As Illumina transitions to its new NovaSeq X platform and implements cost ... Additionally, the long-read sequencing market, where Illumina has a less dominant position, is gaining traction.
2017) and barcoded using standard Illumina ... configuration on a NovaSeq 6000 SP Flowcell (Roy J Carver Biotechnology Center, University of Illinois). All alpha diversity analyses were conducted with ...
The library preparation was performed using Illumina ... Novaseq 6,000 using 150PE chemistry. Paired end sequencing of the transcriptomes of the three biological replicates of the MDR (E. coli IPE) ...
Paired-end sequencing is performed using the Illumina NovaSeq 6000 sequencing platform in PE150 sequencing ... Future studies should focus on elucidating these mechanisms through in-depth functional ...
These solutions leverage the power of Illumina's leading NovaSeq X series platform and will enable researchers to derive breakthrough insights around the drivers of disease. The company will also ...
Illumina is raising the curtain on its upcoming ... The company said its spatial technology will run on its current NextSeq and NovaSeq hardware through a new multimodal software platform, with ...
Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since ...
While Illumina has faced pricing headwinds, particularly with the NovaSeq X transition ... investment decisions with InvestingPro’s in-depth analysis and exclusive insights on ILMN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results